Methotrexate Teva (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate levels. This limits the synthesis of nucleotides required for DNA, RNA, and protein production, thereby suppressing rapidly dividing immune cells and cancer cells.

The specific dose and dosing schedule of Methotrexate Teva are determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and treatment response. No universal dosing regimen is provided here.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk.

To order Methotrexate Teva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with biologic DMARDs, methotrexate is an oral or parenteral small‑molecule agent that is less expensive but may require more laboratory monitoring. In oncology, it offers a distinct mechanism from alkylating agents and taxanes, providing an alternative for patients with specific hematologic or solid‑tumor indications.

Methotrexate Teva should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and handle with gloves if the formulation is a parenteral solution.

Methotrexate Teva is supplied for parenteral use and may be given via epidural, intrabursal, or intracoronary injection, depending on the clinical indication. Administration is performed by qualified healthcare professionals following aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute renal failure, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of organ dysfunction and infection.

Methotrexate Teva should not be used by pregnant women, individuals with severe renal or hepatic impairment, patients with uncontrolled infections, or those who have had hypersensitivity reactions to methotrexate or any component of the formulation.